Drugs / VXCO-102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07557602 | May 2026 → Aug 2027 expected | Epstein-Barr virus infection | Vaccine Company, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VXCO-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07557602 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA Vaccine Targeting Epstein-Barr Virus (EBV)” NCT07557602 ↗ |
| Route | Intramuscular | “Dose 1 - VXCO-102 administered IM by needle and syringe at Day 1 and Week 8” NCT07557602 ↗ |